Skip to main content

Protocol C

Type:
Natural history / prespective cohort
Study Status:
Ongoing
Enrollment Status:
Open
Countries:
Kenya;Uganda;Rwanda;Zambia;South Africa
Partners:
Kenya AIDS Vaccine Initiative-Kangemi (KAVI-Kangemi), Nairobi, Kenya; Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya; Kenya Medical Research Institute-Centre for Geographic Medicine Research-Coast (KEMRI-CGMRC), Kilifi, Kenya; Medical Research Council (MRC-Entebbe)-Entebbe, Uganda; Medical Research Council (MRC-Masaka)-Masaka, Uganda; Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI)-Entebbe, Uganda; Projet San Francisco (PSF-Kigali)-Kigali, Rwanda; Zambia-Emory Research Project (ZEHRP)-Copperbelt, Kitwe, Zambia; Zambia-Emory Research Project (ZEHRP)-Copperbelt-Ndola, Zambia; Zambia-Emory Research Project (ZEHRP)-Lusaka, Zambia; Aurum Institute, Rustenburg, South Africa; Desmond Tutu HIV Foundation (DTHF), Cape Town, South Africa.

 
Study Summary:
 
To evaluate clinical, laboratory, immunologic and viral markers of disease progression in volunteers with recent HIV infection to prepare for activities relevant to the execution of preventive HIV vaccine efficacy trials.  If identifiable and willing, HIV-infected partner(s) of enrolled volunteers will be assessed for virologic and immunogenetic parameters relevant to transmission.